In addition, MIR34A, which is a crucial regulator of tumor suppressor and is upregulated during early-stage PTC [38], may inhibit MAP2K1. However, the expression level of MAP2K1 is still greater than MIR34A, and we deduce this might enhance cancer progression. The gene discussed is MAP2K1; the disease is cancer.